The reason why the L.E.A.P.S. technology lends itself to creating a much more effective immune therapy against the H1N1 flu virus is because the L.E.A.P.S. conjugates induce an effective and powerful immune response without causing excessive amounts of pro-inflammatory cytokines. In the case of prior pandemic influenza, such as the "Spanish Influenza" and more recently the "Avian Flu", patients with stronger immune systems had a greater chance of dying because their immune response was too strong (too many pro-inflammatory cytokines). This is called a cytokine storm. While normally many cytokines play a key role in preventing and treating swine flu, in some cases excessive cytokine amounts may exacerbate the disease as it appears that, unlike the normal flu which affects the very young and very old most severely, swine flu may be more like the avian flu which hits people in their prime more severely.
In addition, LEAPS conjugates may be used to potentially overcome the virus' mutations by focusing on more conserved and common epitopes critical for critical viral function.
The L.E.A.P.S. technology is a novel T-cell modulation platform technology that enables CEL-SCI to design and synthesize proprietary immunogens. Any disease for which an antigenic sequence has been identified, such as infectious, parasitic, malignant or autoimmune diseases and allergies, are potential therapeutic or preventive sites for the application of L.E.A.P.S. technology. Each L.E.A.P.S. construct is composed of a T cell binding ligand (TCBL) which has previously demonstrated the ability to induce and elicit protective immunity and antigen specific antibody production in
|SOURCE CEL-SCI Corporation|
Copyright©2009 PR Newswire.
All rights reserved